Back to Search Start Over

Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.

Authors :
Mazzon E
Esposito E
Di Paola R
Impellizzeri D
Bramanti P
Cuzzocrea S
Source :
Pharmacological research [Pharmacol Res] 2011 Jul; Vol. 64 (1), pp. 68-79. Date of Electronic Publication: 2010 Dec 28.
Publication Year :
2011

Abstract

Olprinone is a specific phosphodiesterase (PDE)-III inhibitor, which has been found to have anti-inflammatory effects in addition to its main inotropic and peripheral vasodilatory effects. In the present study we investigated the effects of olprinone (0.2mg/kg, i.p.) on the development of zymosan-induced multiple organ failure in mice. Treatment with olprinone attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. Olprinone also attenuated the lung, liver and pancreatic injury, renal dysfunction as well as the increased lung and intestine myeloperoxidase (MPO) activity caused by zymosan. Immunohistochemical analysis for inducible nitric oxide synthase (iNOS), nitrotyrosine, poly(ADP-ribose) (PAR), tumor necrosis factor-α (TNF-α) and interleuchin-1β (IL-1β) revealed positive staining in pancreatic and intestinal tissue obtained from zymosan-injected mice. The degree of staining for nitrotyrosine, iNOS, PAR, TNF-α and IL-1β was markedly reduced in tissue sections obtained from zymosan-injected mice, which had received olprinone. In addition, administration of zymosan caused a severe illness in the mice characterized by significant loss of body weight and a 60% of mortality at the end of observation period (7 days). Treatment with olprinone significantly reduced the development of systemic toxicity, loss in body weight and mortality, caused by zymosan. This study provides evidence that olprinone attenuates the degree of zymosan-induced shock in mice.<br /> (Copyright © 2011 Elsevier Ltd. All rights reserved.)

Subjects

Subjects :
Alanine Transaminase blood
Alkaline Phosphatase blood
Amylases blood
Animals
Apoptosis drug effects
Ascitic Fluid drug effects
Ascitic Fluid metabolism
Ascitic Fluid pathology
Aspartate Aminotransferases blood
Bicarbonates blood
Bilirubin blood
Blood Gas Analysis
Body Weight drug effects
Cell Count
Creatinine blood
Fas Ligand Protein metabolism
Hydrogen-Ion Concentration
Imidazoles administration & dosage
Imidazoles pharmacology
Intercellular Adhesion Molecule-1 metabolism
Interleukin-1beta blood
Interleukin-1beta metabolism
Kidney drug effects
Kidney metabolism
Kidney physiopathology
Lipase blood
Liver drug effects
Liver metabolism
Liver pathology
Lung drug effects
Lung physiopathology
Male
Mice
Mice, Inbred Strains
Multiple Organ Failure blood
Multiple Organ Failure metabolism
Multiple Organ Failure pathology
Multiple Organ Failure physiopathology
Nitrates blood
Nitrates metabolism
Nitrites blood
Nitrites metabolism
P-Selectin metabolism
Pancreas drug effects
Pancreas metabolism
Pancreas pathology
Phosphodiesterase 3 Inhibitors administration & dosage
Phosphodiesterase 3 Inhibitors pharmacology
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerases metabolism
Proto-Oncogene Proteins c-bcl-2 metabolism
Pyridones administration & dosage
Pyridones pharmacology
Survival Analysis
Tumor Necrosis Factor-alpha blood
Tumor Necrosis Factor-alpha metabolism
Tyrosine analogs & derivatives
Tyrosine metabolism
Zymosan administration & dosage
Zymosan pharmacology
bcl-2-Associated X Protein metabolism
Imidazoles therapeutic use
Multiple Organ Failure chemically induced
Multiple Organ Failure prevention & control
Phosphodiesterase 3 Inhibitors therapeutic use
Pyridones therapeutic use

Details

Language :
English
ISSN :
1096-1186
Volume :
64
Issue :
1
Database :
MEDLINE
Journal :
Pharmacological research
Publication Type :
Academic Journal
Accession number :
21193041
Full Text :
https://doi.org/10.1016/j.phrs.2010.12.010